Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
274 studies found for:    "systemic scleroderma"
Show Display Options
RSS Create an RSS feed from your search for:
"systemic scleroderma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
Condition: SYSTEMIC SCLERODERMA
Interventions: Drug: standard of care;   Procedure: stem cell transplantation
2 Completed Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Condition: Systemic Scleroderma
Interventions: Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
3 Withdrawn Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
4 Completed Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Condition: Systemic Scleroderma
Interventions: Drug: Sildenafil;   Drug: placebo
5 Completed Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Procedure: standardized reeducation and readaptation program
6 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
7 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
8 Terminated Immunoadsorption in Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Device: TheraSorb Ig
9 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
10 Recruiting Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
11 Recruiting Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
Conditions: SYSTEMIC SCLERODERMA;   ALLOGENEIC MESENCHYMAL STEM CELLS;   ADULT
Intervention: Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
12 Unknown  Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Nilotinib (Tasigna)
13 Active, not recruiting Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Interventions: Other: Internet-based self-management program;   Other: Scleroderma book
14 Completed Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Intervention: Other: Followup survey
15 Unknown  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Imatinib Mesylate
16 Completed Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
17 Recruiting Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Intervention: Drug: Campath
18 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
19 Completed Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
20 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.